Effect of vitamin D supplementation on serum sclerostin levels in chronic kidney disease. by Yadav, AK et al.
Accepted Manuscript
Title: Effect of vitamin D supplementation on serum sclerostin
levels in chronic kidney disease
Authors: Ashok Kumar Yadav, Vivek Kumar, Debasish
Banerjee, Krishan Lal Gupta, Vivekanand Jha
PII: S0960-0760(18)30008-6
DOI: https://doi.org/10.1016/j.jsbmb.2018.01.007
Reference: SBMB 5103
To appear in: Journal of Steroid Biochemistry & Molecular Biology
Received date: 3-11-2017
Revised date: 2-1-2018
Accepted date: 5-1-2018
Please cite this article as: Yadav AK, Kumar V, Banerjee D, Gupta KL, Jha
V, Effect of vitamin D supplementation on serum sclerostin levels in chronic
kidney disease, Journal of Steroid Biochemistry and Molecular Biology (2010),
https://doi.org/10.1016/j.jsbmb.2018.01.007
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
 1 
Effect of vitamin D supplementation on serum sclerostin levels in 
chronic kidney disease 
Running head: Vitamin D supplementation and serum Sclerostin in CKD  
 
Ashok Kumar Yadav1, Vivek Kumar1, Debasish Banerjee2, Krishan Lal Gupta1, Vivekanand 
Jha1,3,4 
 
1Department of Nephrology, Postgraduate Institute of Medical Education and Research, 
Chandigarh, India 
2Renal and Transplantation Unit, St George’s University Hospitals NHS Foundation Trust, 
Molecular and Clinical Sciences Research Institute, St Georges, University of London, United 
Kingdom 
3The George Institute for Global Health, New Delhi, India 
4University of Oxford, Oxford, England, United Kingdom 
 
 
Word count: 1536 
 
Correspondence to: Dr Ashok Kumar Yadav, Department of Nephrology, Postgraduate 
Institute of Medical Education and Research, Chandigarh-160012, India 
Email: mails2ashok@gmail.com 
 
 
Highlights: 
 Serum sclerostin level correlated with 25(OH) D at baseline in CKD Subjects. 
 Cholecalciferol supplementation did not lead to change in serum sclerostin. 
 Change in  serum sclerostin level at 16 weeks correlated with change in eGFR and 
change in serum uric acid. 
 
Abstract 
 
Vitamin D deficiency, cardiovascular disease and abnormal bone mineral metabolism are 
common in chronic kidney disease (CKD). Abnormal bone mineral metabolism has been 
linked to vascular calcification in CKD. Sclerostin has emerged as an important messenger in 
cross talk between bone-vascular axis. We analyzed sclerostin in subjects who participated in 
the randomized, double blind, placebo controlled trial investigating the effect of cholecalciferol 
supplementation on vascular function in non-diabetic CKD stage G3-4 and vitamin D 
≤20ng/ml [CTRI/2013/05/003648]. Patients were randomized (1:1) to receive either two 
directly observed oral doses of 300,000 IU of cholecalciferol or matching placebo at baseline 
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and 8 weeks.  Of the 120 subjects enrolled, 58 in the cholecalciferol group and 59 in the placebo 
group completed the study. At baseline, serum levels of sclerostin were similar in both groups 
(cholecalciferol - median;190pg/ml, IQR;140-260pg/ml and placebo - median;180pg/ml, IQR; 
140-240pg/ml, p=0.67). 16 weeks after cholecalciferol supplementation, there was no change 
in level of sclerostin (mean change;1.10 pg/ml, 95%CI; -27.34 to 29.34 pg/ml, p=0.25). 
However, a significant decrease in sclerostin level was noted in the placebo group (mean 
change; -31.94pg/ml, 95%CI; -54.76 to -9.13 pg/ml, p=0.002). Change (∆) in sclerostin level 
at 16 weeks correlated negatively with ∆ eGFR (r=-0.20, p=0.03) and positively with ∆uric 
acid (r=0.37, p<0.001) but not with ∆25(OH) D (r=0.06, p=0.54), ∆ iPTH (r=-0.03, p=0.78) 
∆FGF23 (r=-0.08, p=0.38) and ∆1,25 (OH)2 D (r=-0.04, p=0.65). In conclusion, high dose 
cholecalciferol supplementation did not change sclerostin levels in non-diabetic stage 3-4 CKD 
subjects. 
 
Keywords: Sclerostin, vitamin D, parathyroid, chronic kidney disease, cardiovascular disease 
 
Background 
 
Chronic kidney disease-mineral bone disorder (CKD-MBD), is the name given to 
abnormalities in mineral and hormone metabolism which lead to declining bone health, 
cardiovascular disease and high mortality[1-3]. Abnormal circulation level of bone biomarkers 
including fibroblast growth factor 23 (FGF-23)[4], bone-specific alkaline phosphatase[5, 6] 
and parathyroid hormone (PTH)[7]  have been shown to be associated with adverse clinical 
outcomes, leading to suggestion that CKD-MBD represents a state of crosstalk between bone 
and vascular axis in CKD.   
In recent years sclerostin, a 190-amino acid glycoprotein produced mainly by osteocytes, has 
emerged as new player in this crosstalk. A soluble Wnt inhibitor, sclerostin binds to low density 
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lipoprotein related receptor 5 and 6 (LRP5/6) and frizzled co-receptor to inhibit bone formation 
by osteocytes[8, 9]. Patients with CKD exhibit high sclerostin levels[10].  Sclerostin interacts 
with fibroblast growth factor 23 (FGF23) [11], vitamin D [11, 12], and parathyroid hormone 
(PTH) [13-15].  
Vitamin D modulates the secretion of sclerostin from osteocytes, and could represent a way to 
modulate its levels. A recent report showed an inverse correlation between levels of the two 
compounds in healthy postmenopausal women [16]. Correction of vitamin D deficiency led to 
decline in sclerostin [17, 18]. In contrast, other studies showed an increase in sclerostin 
following supplementation with native [12, 19] or activated forms of vitamin D in non-CKD 
and CKD subjects [20]. 
 
We evaluated sclerostin levels and its association with mineral bone parameters, and the effect 
of cholecalciferol supplementation on sclerostin levels in subjects with non-diabetic CKD G3-
4 and vitamin D deficiency.  
 
Subjects and Methods: 
 
The study was done on existing samples (stored in biobank) and data of a randomized, double 
blind, placebo-controlled trial to examine the effect of correction of vitamin D deficiency on 
vascular function in subjects with early CKD done at the Postgraduate Institute of Medical 
Education and Research, Chandigarh, India after approval of Institute Ethics Committee [21] 
with only addition of measurement of serum sclerostin. The detailed study protocol has been 
published[21]. In brief, 120 stable non-diabetic, CKD stage G3-4 subjects between ages of 18 
and 70 years and serum 25(OH)D 20 ng/ml were randomized in a 1:1 ratio to receive two 
doses of either 300,000 IU of cholecalciferol or matching placebo at baseline and 8 weeks.  
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Biochemical parameters were measured at baseline and at after 16 weeks. Serum 25(OH)D and 
1,25(OH)2D were measured by enzyme immunoassay [EIA; Immunodiagnostic Systems 
(IDS), UK]. Serum sclerostin was analysed by Quantikine ELISA (R&D System, USA).  
Serum intact parathyroid hormone (iPTH; EIA, Calbiotech Inc., USA), serum intact fibroblast 
growth factor-23 [FGF-23; second generation enzyme linked immunosorbent assay (ELISA), 
Immutopics, Diagnostic Hybrids Inc., USA], were also analyzed.  
 
Statistical analysis 
Data are presented as mean ± standard deviation, mean (95% confidence interval) and median 
(interquartile range) as appropriate. Continuous variables were compared with independent 
samples Student’s t test if normally distributed, or with Mann-Whitney U test if the distribution 
was skewed. Categorical variables were analyzed by Chi Square test or Fisher’s Exact test as 
appropriate. Paired Student’s t-test and Wilcoxon signed-rank test were used for within-group 
comparisons. Correlation analysis was performed using Pearson correlation or Spearman’s 
rank correlation as appropriate. Two tailed p-values <0.05 were considered statistically 
significant. Analyses were conducted using the Statistical Package for the Social Sciences 
(SPSS) software for Macintosh, version 21.0 (IBM Corp., Armonk, NY, USA).  
 
Results: 
 
Baseline characteristics of the study subjects are shown in table 1. Biochemical parameters and 
circulating biomarker levels did not differ between the groups. The demographic details, causes 
of CKD and use of medications were also similar[21].  
 
Baseline analysis 
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Baseline sclerostin levels were similar in the two groups (cholecalciferol - median; 190 pg/ml, 
IQR;140-260 pg/ml and placebo - median;180 pg/ml, IQR; 140-240 pg/ml, p=0.67). Sclerostin 
levels correlated positively with age (r=0.44, p<0.001), 25(OH) vitamin D (r=0.24, p=0.01), 
serum uric acid (r= 0.27, p=0.004) and FGF23 (r=0.20, p=0.02), and inversely with BMI (r=-
0.21, p=0.03), iPTH (r=-0.23, p=0.01) and SAP (r=-0.25, p=0.009) (Figure1). eGFR was not 
significantly correlated with sclerostin level but a trend of negative association was noted (r=-
0.13, p=0.16) (Figure1).  Levels were higher in males (median 190 pg/ml, IQR; 160-260 pg/ml) 
compared to females (median 160 pg/ml, IQR; 130-210 pg/ml, p=0.04). 
 
Follow-up analysis 
After 16 weeks sclerostin levels remained unchanged in the cholecalciferol treated subjects 
(mean change;1.10 pg/ml, 95%CI; -27.34 to 29.34 pg/ml, p=0.25), whereas a significant 
decrease was noted in the placebo group (mean change; -31.94 pg/ml, 95%CI; -54.76 to -9.13 
pg/ml, p=0.002). The between group difference in mean change, however, remained non-
significant (Table 2). Response to cholecalciferol or placebo remained similar in both males 
and females (data not shown). Change (∆) in sclerostin level correlated negatively with ∆ eGFR 
(r=-0.20, p=0.03) and positively with ∆uric acid (r=0.37, p<0.001) but not with ∆25(OH) D 
(r=0.06, p=0.54), ∆iPTH (r=-0.03, p=0.78) ∆FGF23 (r=-0.08, p=0.38) and ∆1,25 (OH)2 D (r=-
0.04, p=0.65). As shown in table 2, the serum 25(OH)D and 1,25(OH)2D levels increased in 
the cholecalciferol group, but not in the placebo group. There was a decline in iPTH in the 
cholecalciferol group but rise in the placebo group.  
 
Discussion 
In this randomized double-blind placebo controlled trial setting, supplementation of 
cholecalciferol did not affect the sclerostin level in non-diabetic CKD G3-4 subjects. Although 
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level declined in the control group, the intergroup difference was not significant. We also show 
that serum level of sclerostin is associated with demographic characteristic like age, gender 
and BMI as well as with mineral metabolism markers including 25(OH) vitamin D, iPTH, SAP 
and FGF23. 
 
The consequences of increased sclerostin levels on outcomes in CKD are not clear. Sclerostin 
has been associated with decline in GFR[10], progression of renal osteodystrophy[22], 
hyperparathyroidism and bone turnover[23]. In CKD stage 3-5, increased sclerostin levels are 
associated with abnormality in parameters of CKD-MBD and vascular function. Notably, in 
predialysis CKD cohort, sclerostin levels are associated with increased incidence in mortality 
and severe cardiovascular events [24]. 
 
There is interest in understanding whether manipulation of sclerostin represents a worthwhile 
therapeutic goal, and if so how this might be achieved. Studies of native vitamin D 
supplementation have produced conflicting results. Correction of vitamin D deficiency has 
been shown to decrease sclerostin in vitamin D deficient adult females[18] and vitamin D 
deficient general population[17]. By contrast, Sankaralingam et al showed increase in 
sclerostin level after vitamin D2 supplementation in vitamin D deficient patients[19]. An 
increase in sclerostin was also shown in CKD subjects after paricalcitol treatment[20]. In a 
large placebo controlled trial, 700 IU per day vitamin D and 500 mg per day calcium in men 
and women age 65 years and older produced an increase of sclerostin level in men, whereas it 
remained unchanged in women [12]. The reason for the differential sclerostin responses to 
vitamin D and calcium supplementation in the men and the women is unclear. In our study, 
sclerostin level remained unchanged after cholecalciferol supplementation in spite of decline 
in PTH. Vitamin D supplementation decrease serum PTH levels[21, 25], and being negative 
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regulator of sclerostin expression [14, 26] decline in PTH should increase serum sclerostin. 
Cross- sectional studies have identified inverse associations of serum sclerostin with a variety 
of biochemical markers of bone turnover [27-29] and the same has been confirmed in the 
present study. 
 
Our study has strengths and limitations. The strength is the setting of randomized double-
blinded, placebo-controlled trial, homogenous study population, and adequate sample size. The 
limitation of the study was short duration. Serum calcium level should be monitored as it may 
rise with vitamin D therapy. 
 
Conclusion 
In conclusion, high dose cholecalciferol supplementation did not alter serum sclerostin in CKD 
patients despite decline in other mineral markers such as PTH and SAP. Further studies are 
needed to fully elucidate the effect of vitamin D on sclerostin level in subjects with CKD. 
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Figure legend: 
 
Figure 1: Scatter plot showing association of serum level of sclerostin with anthropometric and 
serum biomarkers.    eGFR, estimated glomerular filtration rate; 25(OH)D, 25 hydroxy vitamin 
D; iPTH, intact parathyroid hormone; iFGF-23, intact fibroblast growth factor-23; SAP, total 
serum alkaline phosphatase; BMI, body mass index 
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Table 1: Baseline characteristics of study subjects 
Parameter Placebo (n=59) Cholecalciferol 
(n=58) 
Gender (M/F) 40/19 41/17 
Age (years) 45.20±11.61 43.17±11.79 
Body mass index (kg/m2) 23.45±2.91 23.57±2.67 
Hemoglobin (g/dl) 12.02±1.94 11.97±1.69 
eGFR (min/ml/1.73m2) 34.63±12.25 35.77±12.37 
Albumin (g/dl) 4.62±0.63 4.74±0.54 
Calcium (mg/dl) 9.09±0.94 9.01±0.73 
Inorganic Phosphorus (mg/dl) 4.03±1.39 3.65±0.91 
Uric Acid (mg/dl) 7.66±2.37 8.01±2.32 
SAP (U/L) 136.07±59.83 135.17±58.32 
25(OH)D (ng/ml) 13.21±4.78 13.40±4.42 
1,25 (OH)2 D(pg/ml) 20.11±12.54 19.10±10.69 
iPTH (pg/ml)* 150 (100, 250) 140(80, 210) 
iFGF-23 (pg/ml) * 57.66 (44.48, 88.90) 57.88 (41.42, 69.04) 
Sclerostin (pg/ml) * 190 (140,260)  180 (140,240) 
Abbreviations: eGFR, estimated glomerular filtration rate; 25(OH)D, 25 hydroxy vitamin D; 
1,25 (OH)2 D, 1,25 di-hydroxy vitamin D; iPTH, intact parathyroid hormone; iFGF-23, intact 
fibroblast growth factor-23; SAP, total serum alkaline phosphatase;  
Data presented as mean± standard deviation and median (25th, 75th percentile) 
* Compared using Mann-Whitney U test 
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Table 2: Change in biochemical parameters and markers of bone turnover between baseline and 16 weeks 
  Placebo (n=59) Cholecalciferol (n=58) Between group difference 
 
  Mean change  
(95% CI) 
P value Mean change  
(95% CI) 
P value Difference of Mean change 
(95% CI) 
P value 
25(OH)D (ng/ml) 1.51 (-0.46 to 3.48) 0.13 24.91 (21.77 to 28.06) <0.001 23.40 (19.76 to 27.06) <0.001 
1,25 (OH)2 D (pg/ml) 0.48 (-4.65 to 5.62) 0.85 15.46 (5.42 to 25.50) 0.003 14.98 (4.48 to 27.18) 0.007 
i-PTH (pg/ml) * 47.36 (6.63 to 88.10) 0.05 -53.37 (-82.37 to -24.36) <0.001 -100.73 (-150.50 to -50.95) <0.001 
iFGF-23 (pg/ml) * -7.33 (-24.10 to 9.45) 0.27 -14.71 (-28.45 to -0.97) 0.33 -7.38 (-28.92 to 14.15) 0.96 
SAP (U/L) 9.40 (-2.08 to 20.89) 0.11 -10.85 (-20.70 to -1.01) 0.03 -20.25 (-35.14 to -5.38) 0.008 
Sclerostein (pg/ml)* -31.94(-54.76 to-9.13) 0.002 1.1(-27.34 to 29.34) 0.25 -33.04 (-69.14 to 3.05) 0.07 
Uric Acid (mg/dl) -0.51 (-0.67 to 0.08) 0.09 -0.60 (-1.12 to -0.03) 0.04 -0.09 (-0.89 to 0.72) 0.83 
Calcium (mg/dl) -0.48 (-0.76 to -0.19) 0.001 0.21 (-0.05 to 0.46) 0.11 0.69 (0.31 to 1.06) 0.001 
Inorganic 
Phosphorus (mg/dl) 
-0.30 (-0.67 to 0.08) 0.12 0.19 (-0.19 to 0.59) 0.31 0.49 (-0.37 to 1.03) 0.07 
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Abbreviations: eGFR, estimated glomerular filtration rate; 25(OH)D, 25 hydroxy vitamin D; 1,25 (OH)2 D, 1,25 di-hydroxy vitamin D; iPTH, 
intact parathyroid hormone; iFGF-23, intact fibroblast growth factor-23; SAP, total serum alkaline phosphatase;  
*Compared using Willcoxon-signed rank test within group and Mann-Whitney U test between group 
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